Omeros Corp. (OMER), a clinical-stage biopharmaceutical company, Tuesday said it has filed a Clinical Trial Application or CTA with European regulators to initiate clinical trials evaluating OMS721, the company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 or MASP-2 program.
The lead indication for OMS721 will be atypical hemolytic uremic syndrome, a rare but life-threatening form of thrombotic microangiopathy. Assuming positive regulatory review of its CTA, Omeros plans to initiate a Phase 1 clinical trial evaluating OMS721 early next quarter.
For comments and feedback: editorial@rttnews.com